Intelligent Bio Solutions (NASDAQ:INBS – Get Free Report) and DexCom (NASDAQ:DXCM – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.
Risk & Volatility
Intelligent Bio Solutions has a beta of 4.48, meaning that its share price is 348% more volatile than the S&P 500. Comparatively, DexCom has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500.
Institutional and Insider Ownership
33.0% of Intelligent Bio Solutions shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 2.8% of Intelligent Bio Solutions shares are held by company insiders. Comparatively, 0.3% of DexCom shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Intelligent Bio Solutions and DexCom”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Intelligent Bio Solutions | $4.22 million | 1.38 | -$12.43 million | ($6.38) | -0.28 |
| DexCom | $4.66 billion | 6.67 | $836.30 million | $2.55 | 32.68 |
DexCom has higher revenue and earnings than Intelligent Bio Solutions. Intelligent Bio Solutions is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Intelligent Bio Solutions and DexCom’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Intelligent Bio Solutions | -269.28% | -150.00% | -83.38% |
| DexCom | 19.42% | 37.77% | 15.98% |
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Intelligent Bio Solutions and DexCom, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Intelligent Bio Solutions | 1 | 1 | 0 | 0 | 1.50 |
| DexCom | 0 | 2 | 24 | 2 | 3.00 |
DexCom has a consensus target price of $95.50, indicating a potential upside of 14.60%. Given DexCom’s stronger consensus rating and higher possible upside, analysts clearly believe DexCom is more favorable than Intelligent Bio Solutions.
Summary
DexCom beats Intelligent Bio Solutions on 13 of the 15 factors compared between the two stocks.
About Intelligent Bio Solutions
Intelligent Bio Solutions Inc. is a medical technology company focused on non-invasive testing and diagnostic solutions. Its flagship offering is the Intelligent Fingerprinting Drug Screening System, which analyzes trace sweat collected from a person’s fingertips to screen for drugs. The system combines a portable reader with single-use fingerprint test cartridges. Its compact format is designed for use in settings such as workplaces, law enforcement, drug treatment and rehabilitation programs, and other organizations that conduct screening.
About DexCom
DexCom, Inc. develops and markets continuous glucose monitoring (CGM) systems for people with diabetes. Its wearable sensors measure glucose levels throughout the day and send readings to compatible receivers or mobile devices, helping users monitor glucose trends and support treatment decisions. The company’s products include its Dexcom G6 and G7 CGM systems, along with software and connected services for users and caregivers. DexCom also offers Stelo, an over-the-counter glucose biosensor designed for adults who do not use insulin.
Receive News & Ratings for Intelligent Bio Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intelligent Bio Solutions and related companies with MarketBeat.com's FREE daily email newsletter.
